← Eichor
Study identifier: NCT06738303 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

Condition: Metastatic Prostate Cancer · Metastatic Castration-resistant Prostate Cancer  ·  Sponsor: Case Comprehensive Cancer Center

PhasePhase 2
Planned participants44
Who can joinAll sexes, 19 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to find out what treatment works best for participants with metastatic prostate cancer that are not responding to hormone treatment and docetaxel and are also Prostate-specific membrane antigen(PSMA) positive.

This description comes directly from the study's public registry record.

Talk to the study team

Pedro Barata, MD, MSc  ·  216-262-1214  ·  Pedro.Barata@UHhospitals.org

Always discuss trial participation with your own doctor first.

Locations (1)

Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland Clinic Taussig Cancer CenterCleveland, Ohio, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06738303